Sicca Syndrome (Sjogren) – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Sicca Syndrome (Sjogren) – Drugs In Development, 2024 report and make more profitable business decisions.
Sjogren’s syndrome is an autoimmune disease. It involves the inflammation of glands and other tissues of the body. Symptoms include skin rashes or dry skin, vaginal dryness, persistent dry cough, prolonged fatigue, dry eye, dry mouth, joint pain, swelling, and stiffness. Predisposing factors include age, sex, and rheumatic disease.
The Sicca Syndrome (Sjogren) drugs in development market research report provide comprehensive information on the therapeutics under development for Sicca Syndrome (Sjogren), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Sicca Syndrome (Sjogren) and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Sicca Syndrome (Sjogren) | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 56 molecules, with 54 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Sicca Syndrome (Sjogren) therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Sicca Syndrome (Sjogren) pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Sicca Syndrome (Sjogren) treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Ainos IncAldeyra Therapeutics Inc
Alpine Immune Sciences Inc
Amytrx Therapeutics Inc
Argenx SE
AstraZeneca Plc
Astria Therapeutics Inc
Beijing Toll Biotech Co Ltd
Boston Immune Technologies and Therapeutics Inc
Bristol-Myers Squibb Co
Cell2Cure Aps
CellAxia Inc
Chongqing Precision Biotech Co Ltd
Curexsys GmbH
Eli Lilly and Co
HiFiBiO Therapeutics Inc
Horizon Therapeutics Plc
HotSpot Therapeutics Inc
I-Mab
Ibex Bioscience Inc
Iltoo Pharma
IMIDomics Inc
ImmuneID Inc
ImmunoQure AG
Innovent Biologics Inc
Japan Tobacco Inc
Johnson & Johnson
KALA BIO Inc
MeiraGTx Holdings Plc
MimeTech Srl
Novartis AG
OSE Immunotherapeutics SA
PB Immune Therapeutics Co Ltd
Peking University People's Hospital
RemeGen Co Ltd
Resolve Therapeutics LLC
Rise Therapeutics LLC
Rophibio Inc
Samjin Pharm Co Ltd
Sanofi
Shanghai YaKe Biotechnology Co Ltd
Simcere Pharmaceutical Group Ltd
SinoMab Bioscience Ltd
Spectrix Therapeutics LLC
Surrozen Inc
TearSolutions Inc
Tonix Pharmaceuticals Holding Corp
Trefoil Therapeutics LLC
University of Queensland
XTL Biopharmaceuticals Ltd
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Sicca Syndrome (Sjogren) reports